Cited by 412Systemic Lupus Erythematosus ResearchSystemic Sclerosis and Related DiseasesVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus

Ruiz-Irastorza, G, Egurbide, M-V, Pijoan, J-I, Garmendia, M, Villar, I, Martinez-Berriotxoa, A, Erdozain, J-G, Aguirre, C·2006·Lupus

DOI 10.1177/0961203306071872

Open this paper in CoChat — free account

Abstract

Antimalarials have shown beneficial effects on systemic lupus erythematosus (SLE) activity. Our aim was to investigate whether antimalarials protect against thrombosis and influence survival in SLE patients. A prospective cohort including 232 patients with SLE were included in the study at the time of lupus diagnosis. End points were documented thrombosis and death due to any cause. A Cox regression-multiple-failure time survival analysis model was fitted to establish the effect of antimalarials on the development of thrombosis. Kaplan-Meier survival curves and propensity score adjusted-Cox regression analysis were performed to investigate the effect of antimalarials use on survival. Of our subjects, 204 patients (88%) were women. 230 patients (99%) were white. 150 patients (64%) had ever received antimalarials. Median time on antimalarials was 52 months (range three to 228 months). The Cox multiple-failure time survival analysis showed that taking antimalarials was protective against thrombosis (HR 0.28, 95%CI 0.08-0.90), while aPL-positivity (HR 3.16, 95%CI 1.45-6.88) and previous thrombosis (HR 3.85, 95%CI 1.50-9.91) increased the risk of thrombotic events. Twenty-three patients died, 19 of whom (83%) had never received antimalarials. No patient treated with antimalarials died of cardiovascular complications. Cumulative 15-year survival rates were 0.68 for never versus 0.95 for ever treated patients ( P < 0.001). Age at diagnosis and propensity score-adjusted HR for antimalarials ever versus never users was 0.14 (95%CI 0.04-0.48). Our study shows a protective effect of antimalarials against thrombosis and an increased survival of SLE patients taking these drugs. These data support the routine use of antimalarials in all patients with SLE.

Integrity signals

Registry

Crossref · 10.1177/0961203306071872

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Age-specific Incidence Rates of Myocardial Infarction and Angina in Women with Systemic Lupus Erythematosus: Comparison with the Framingham Study
Manzi, S., Meilahn, E. N., Rairie, J. E., Conte, C. G., Medsger, T. A., Jansen-McWilliams, L., D’Agostino, R. B., & Kuller, L. H. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009122 · Cited by 1,831
Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus
Roman, M. J., Shanker, B., Davis, A., Lockshin, M. D., Sammaritano, L. R., Simantov, R., Crow, M. K., Schwartz, J. E., Paget, S. A., Devereux, R. B., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035471 · Cited by 1,422
Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Mejía, J. C., Aydintug, A. O., Chwalinska-Sadowska, H., de Ramón, E., et al. (2003) · Medicine · doi:10.1097/01.md.0000091181.93122.55 · Cited by 1,377
Premature Coronary-Artery Atherosclerosis in Systemic Lupus Erythematosus
Asanuma, Y., Oeser, A. M., Shintani, A., Turner, E. L., Olsen, N. J., Fazio, S., Linton, M. F., Raggi, P., & Stein, C. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035611 · Cited by 889
Sequential Therapies for Proliferative Lupus Nephritis
Contreras, G. N., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O'Nan, P., & Roth, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031855 · Cited by 815
Activation of the interferon‐α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease
Kirou, K. A., Lee, C., George, S., Louca, K., Peterson, M. G. E., & Crow, M. K. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21031 · Cited by 702

Show all 48 references

Research works printed but not linked: 3

Rosembaum PR , Rubin DB. The central role of propensity scores in estimating dose-response functions . Biometrika 1983; 70: 41-55 .
10.1177/0961203396005001031 · DOI · Paper page
Alarcón GS , McGwin G, Jr. , Fessler BJ et al. “Confounding by indications” partially explains the protective effect of hydroxychloroquine (HCQ) in SLE survival: Data from a multiethnic US cohort . Arthritis Rheum 2005; 52: S726-S726 .

Sorted by citations

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,735
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
Self-citation
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramón, E., Buonaiuto, V, Jacobsen, S., Zeher, M. M., Tarr, T., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204838 · Cited by 974
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 818
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
van Vollenhoven, R., Mosca, M., Bertsias, G. K., Isenberg, D. A., Kuhn, A., Lerstrøm, K., Aringer, M., Bootsma, H., Boumpas, D., Bruce, I. N., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-205139 · Cited by 761
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS
Rovin, B. H., Ayoub, I. M., Chan, T. M., Liu, Z.-H., Mejia-Vilet, J. M., & Floege, J. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.002 · Cited by 557
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)
Alarcón, G. S., McGwin, G., Bertoli, A. M., Fessler, B. J., Alén, J. C., Bastian, H. M., Vilá, L. M., & Reveille, J. D. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.068676 · Cited by 524
Antiphospholipid syndrome
Schreiber, K. I., Sciascia, S., de Groot, P. G., Devreese, K. M. J., Jacobsen, S., Ruiz‐Irastorza, G., Salmon, J. E., Shoenfeld, Y., Shovman, O., & Hunt, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.103 · Cited by 445
Self-citation
Predictors of major infections in systemic lupus erythematosus
Ruiz‐Irastorza, G., Olivares, N., Ruiz‐Arruza, I., Martínez-Berriotxoa, A., Egurbide, M.-V., & Aguirre, C. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2764 · Cited by 371
Self-citation
The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review
Schoenfeld, S. R., Kasturi, S., & Costenbader, K. H. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.12.002 · Cited by 370
The role of platelets in immune-mediated inflammatory diseases
Scherlinger, M., Richez, C., Tsokos, G. C., Boilard, É., & Blanco, P. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00834-4 · Cited by 375
Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies
Tektonidou, M. G., Laskari, K., Panagiotakos, D. B., & Moutsopoulos, H. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24232 · Cited by 356
Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus
Urowitz, M. B., Gladman, D. D., Tom, B. D. M., Ibañez, D., & Farewell, V. T. (2008) · The Journal of Rheumatology · doi:10.3899/jrheum.080214 · Cited by 327
Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences
Ruiz‐Irastorza, G., Egurbide, M.-V., Olivares, N., Martínez-Berriotxoa, A., & Aguirre, C. (2008) · Rheumatology · doi:10.1093/rheumatology/ken121 · Cited by 331
Self-citation
14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
Erkan, D., Aguiar, C. L., ANDRADE, D. C. O. D., Cohen, H., Cuadrado, M. J., Danowski, A., Levy, R. A., Ortel, T. L., Rahman, A., Salmon, J. E., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.053 · Cited by 322
Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort
Pons‐Estel, G., Alarcón, G. S., McGwin, G., Danila, M. I., Zhang, J., Bastian, H. M., Reveille, J. D., & Vilá, L. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24538 · Cited by 311
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients
Cervera, R., Khamashta, M. A., Shoenfeld, Y., Camps, M. T., Jacobsen, S., Kiss, E., Zeher, M. M., Tincani, A., Kontopoulou-Griva, I., Galeazzi, M., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.093179 · Cited by 286
Epidemiology of systemic lupus erythematosus
Pons‐Estel, G., Ugarte-Gil, M. F., & Alarcón, G. S. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1327352 · Cited by 271
Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug
Rand, J. H., Wu, X.-X., Quinn, A. S., Ashton, A. W., Chen, P. P., Hathcock, J. J., Andree, H. A. M., & Taatjes, D. J. (2010) · Blood · doi:10.1182/blood-2009-04-213520 · Cited by 253
New concepts in antimalarial use and mode of action in dermatology
Kalia, S., & Dutz, J. P. (2007) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2007.00131.x · Cited by 253
Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus
Sacré, K., Criswell, L. A., & McCune, J. M. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3895 · Cited by 243
The role of antimalarial agents in the treatment of SLE and lupus nephritis
Lee, S., Silverman, E. D., & Bargman, J. M. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.150 · Cited by 241
Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives
Magro‐Checa, C., Zirkzee, E. J. M., Huizinga, T. W. J., & Steup‐Beekman, G. M. (2016) · Drugs · doi:10.1007/s40265-015-0534-3 · Cited by 244
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
Dima, A., Jurcuț, C., Chasset, F., Felten, R., & Arnaud, L. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211073001 · Cited by 239
Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis
Rempenault, C., Combe, B. G., Barnetche, T., Gaujoux-Viala, C., Lukas, C., Morel, J., & Hua, C. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211836 · Cited by 221
New insights into mechanisms of therapeutic effects of antimalarial agents in SLE
Wallace, D. J., Gudsoorkar, V. S., Weisman, M. H., & Venuturupalli, S. R. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.106 · Cited by 221
Antimalarial treatment may have a time‐dependent effect on lupus survival: Data from a multinational Latin American inception cohort
Shinjo, S. K., Bonfá, E., WOJDYLA, D. M., Borba, E. F., Ramírez, L. A., Scherbarth, H. R., Brenol, J. C. T., Chacón-Díaz, R., Neira, O. J., Berbotto, G. A., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27300 · Cited by 208
Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody–Positive Patients
Petri, M. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-010-0141-y · Cited by 206
Hydroxychloroquine retinopathy — implications of research advances for rheumatology care
Jorge, A. M., Ung, C., YOUNG, L. H. Y., Melles, R. B., & Choi, H. K. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0111-8 · Cited by 206
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies
Sciascia, S., Hunt, B. J., Talavera-García, E., Lliso-Ribera, G., Khamashta, M. A., & Cuadrado, M. J. (2015) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.09.078 · Cited by 201
Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus
Ja, J., Kim-Howard, X., Bruner, B. F., Jonsson, M., McClain, M. T., Arbuckle, M., Walker, C., Dennis, G., Merrill, J. T., & Harley, J. (2007) · Lupus · doi:10.1177/0961203307078579 · Cited by 197
Hydroxychloroquine: A multifaceted treatment in lupus
Costedoat-Chalumeau, N., Dunogué, B., Morel, N., Guern, V. L., & Guettrot-Imbert, G. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.03.007 · Cited by 195
Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence
Durcan, L., Clarke, W. A., Magder, L. S., & Petri, M. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.150379 · Cited by 190
Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival
Sisó, A., Ramos-Casals, M., Bové, A., Brito-Zerón, P., Soria, N., Muñoz, S., Testi, A., Plaza, J., Sentís, J., & Coca, A. (2008) · Lupus · doi:10.1177/0961203307086503 · Cited by 189
Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort
Willis, R., Seif, A. M., McGwin, G., Martinez-Martinez, L.-A., González, E., Dang, N. N. A., Papalardo, E., LIU, J., Vilá, L., Reveille, J., et al. (2012) · Lupus · doi:10.1177/0961203312437270 · Cited by 190
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus
Urowitz, M. B., Gladman, D. D., Ibañez, D., Bae, S., Sanchez-Guerrero, J., Gordon, C., Clarke, A. E., Bernatsky, S., Fortin, P. R., Hanly, J. G., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20122 · Cited by 187
Advances in the Medical Treatment of Rheumatoid Arthritis
Kahlenberg, J. M., & Fox, D. A. (2010) · Hand Clinics · doi:10.1016/j.hcl.2010.09.002 · Cited by 174
Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients
da Silva, J. C., Mariz, H. D. A., Rocha, L., de Oliveira, P. S. S., Dantas, A. T., Duarte, Â. L. B. P., Pitta, I. D. R., Galdino, S. L., & Pitta, M. G. D. R. (2013) · Clinics · doi:10.6061/clinics/2013(06)07 · Cited by 171
Pharmacology of Chloroquine and Hydroxychloroquine
Browning, D. J. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0597-3_2 · Cited by 170
Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study
Hanly, J. G., Urowitz, M. B., Su, L., Gordon, C., Bae, S., Sánchez‐Guerrero, J., Romero‐Díaz, J., Wallace, D. J., Clarke, A. E., Ginzler, E. M., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201089 · Cited by 168
Self-citation
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
Cohen, H., Cuadrado, M. J., Erkan, D., Duarte‐García, A., Isenberg, D. A., Knight, J. S., Ortel, T. L., Rahman, A., Salmon, J. E., Tektonidou, M. G., et al. (2020) · Lupus · doi:10.1177/0961203320950461 · Cited by 170
Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID ‐19 Pandemic
Michaud, K. D., Wipfler, K., Shaw, Y., Simon, T. A., Cornish, A., England, B. R., Ogdie, A., & Katz, P. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11148 · Cited by 164
The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?
Quirós-Roldán, E., Biasiotto, G., Magro, P., & Zanella, I. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104904 · Cited by 153
Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs
Ruiz‐Irastorza, G., & Bertsias, G. K. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa403 · Cited by 148
Self-citation
The Early Protective Effect of Hydroxychloroquine on the Risk of Cumulative Damage in Patients with Systemic Lupus Erythematosus
Akhavan, P. S., Su, J., Lou, W. Y. W., Gladman, D. D., Urowitz, M. B., & Fortin, P. R. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120572 · Cited by 147
Chloroquine: Modes of action of an undervalued drug
Thomé, R., Lopes, S. C. P., Costa, F. T. M., & Verinaud, L. M. C. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.07.004 · Cited by 151
Multifaceted effects of hydroxychloroquine in human disease
Olsen, N. J., Schleich, M. A., & Karp, D. R. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.01.001 · Cited by 147
Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy
Petri, M., Elkhalifa, M., Li, J., Magder, L. S., & Goldman, D. W. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41121 · Cited by 143
The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis
Rand, J., Xx, W., Quinn, A., & Taatjes, D. J. (2010) · Lupus · doi:10.1177/0961203310361485 · Cited by 143
Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus
Jallouli, M., Galicier, L., Zahr, N., Aumaître, O., Francès, C., Guern, V. L., Lioté, F., Смаил, А., Limal, N., Pérard, L., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39194 · Cited by 136
An update on mortality in systemic lupus erythematosus.
Ippolito, A., & Petri, M. (2008) · PubMed · Cited by 131
HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies
Schreiber, K. I., Breen, K. A., Cohen, H., Jacobsen, S., Middeldorp, S., Pavord, S. R., Regan, L., Roccatello, D., Robinson, S. E., Sciascia, S., et al. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1603359 · Cited by 128
The non-haemostatic role of platelets in systemic lupus erythematosus
Linge, P., Fortin, P. R., Lood, C., Bengtsson, A. A., & Boilard, É. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2018.38 · Cited by 129
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome
Nuri, E., Taraborelli, M., Andreoli, L., Tonello, M., Gerosa, M., Calligaro, A., Argolini, L. M., Kumar, R., Pengo, V., Meroni, P. L., et al. (2017) · Immunologic Research · doi:10.1007/s12026-016-8812-z · Cited by 123
A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye
Costedoat-Chalumeau, N., Dunogué, B., Leroux, G., Morel, N., Jallouli, M., Guern, V. L., Pietté, J. C., Brézin, A. P., Melles, R. B., & Marmor, M. F. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8469-8 · Cited by 123
Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double‐Blind, Randomized, Parallel‐Group Trial
Yokogawa, N., Eto, H., Tanikawa, A., Ikeda, T., Yamamoto, K., Takahashi, T., Mizukami, H., Sato, T. Z., Yokota, N., & Furukawa, F. (2016) · Arthritis & Rheumatology · doi:10.1002/art.40018 · Cited by 122
Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome
Belizna, C. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.12.006 · Cited by 118
Antimalarials may influence the risk of malignancy in systemic lupus erythematosus
Ruiz‐Irastorza, G., Ugarte, A., Egurbide, M.-V., Garmendia, M., Pijoan, J. I., Martínez-Berriotxoa, A., & Aguirre, C. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.067777 · Cited by 118
Self-citation
Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19
Lei, Z., Wu, Z., Dong, S., Yang, D., Zhang, L., Ke, Z., Zou, C., & Chen, Z. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107672 · Cited by 117
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention
McMahon, M. A., Hahn, B. H., & Skaggs, B. J. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.98 · Cited by 115
Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis
Liu, D., Li, X., Zhang, Y., Kwong, J. S. W., Li, L., Zhang, Y., Xu, C., Li, Q., Sun, X., Tian, H., et al. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s166893 · Cited by 116
Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention
Kostopoulou, M., Nikolopoulos, D., Parodis, I., & Bertsias, G. K. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161118666191227101636 · Cited by 114
Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV)
Andrade, R. M., AlarcÃ³n, G. S., González, L., FernÃ¡ndez, M., Apte, M., Vilá, L. M., McGwin, G., & Reveille, J. D. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.077594 · Cited by 114
Pragmatic approaches to therapy for systemic lupus erythematosus
Xiong, W., & Lahita, R. G. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.157 · Cited by 117
The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study
Kravvariti, E., Koutsogianni, A., Samoli, E., Sfikakis, P. P., & Tektonidou, M. G. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102491 · Cited by 115
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Fasano, S., Pierro, L., Pantano, I., Iudici, M., & Valentini, G. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161351 · Cited by 111
Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus
Koh, J. H., Ko, H. S., Kwok, S.-K., Ju, J. H., & Park, S.-H. (2014) · Lupus · doi:10.1177/0961203314555352 · Cited by 106
Hydroxychloroquine Use Is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in Systemic Lupus Erythematosus
BRODER, A., & PUTTERMAN, C. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120157 · Cited by 102
“LAC+ and/or at least 1 aPL ≥ 40 U 25 (28) 20 (22) 17 (19) LAC+ and aPL ≥ 40 U 7 (8) 4 (4) 4 (4) LAC– and aPL ≥ 40 U 6 (7) 2 (2) 1 (1) LAC+ and aPL < 40 U 1 (1) 3 (3) 1 (1) LAC unknown and aPL ≥ 40 U 11 (12) 11 (12) 7 (8) LAC unknown and aPL < 40 U 37 (41) 28 (31) 24 (27) At least 1 aPL ≥ 40 U 24 (27) 17 (19) 16 (18) A…”
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
Almeida-Brasil, C. C., Hanly, J. G., Urowitz, M. B., Clarke, A. E., Ruiz‐Irastorza, G., Gordon, C., Ramsey‐Goldman, R., Petri, M., Ginzler, E. M., Wallace, D. J., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221295 · Cited by 101
Self-citation
Current treatment of systemic lupus erythematosus: a clinician's perspective
Pawlak-Buś, K. K., Schmidt, W., Ewa, D., & Leszczyński, P. (2023) · Rheumatology International · doi:10.1007/s00296-023-05306-5 · Cited by 100
Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients
Pérez-De-Lis, M., Akasbi, M., Sisó‐Almirall, A., Díez-Cascón, P., Brito‐Zerón, P., Díaz‐Lagares, C., Ortiz, J., Pérez-Álvarez, R., Ramos‐Casals, M., & Coca, A. (2010) · Lupus · doi:10.1177/0961203310367504 · Cited by 99
Prednisone in lupus nephritis: How much is enough?
Ruiz‐Irastorza, G., Danza, Ã., Perales, I., Villar, I., Garcia, M., Delgado, S., & Khamashta, M. A. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.013 · Cited by 99
Self-citation
Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy
Abarientos, C., Sperber, K. E., Shapiro, D. L., Aronow, W. S., Chao, C. P., & Ash, J. Y. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.566555 · Cited by 98
Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets
Scherlinger, M., Guillotin, V., Truchetet, M., Contin‐Bordes, C., Sisirak, V., Duffau, P., Lazaro, E., Richez, C., & Blanco, P. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.012 · Cited by 98
Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain
Sabio, J. M., Zamora‐Pasadas, M., Jiménez‐Jáimez, J., Albadalejo, F., Vargas‐Hitos, J. A., del Águila, M. M. R., Hidalgo-Tenorio, C., González-Gay, M. Á., & Alonso, J. (2008) · Lupus · doi:10.1177/0961203308093554 · Cited by 97
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects
Tang, C., Godfrey, T., Stawell, R. J., & Nikpour, M. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02886.x · Cited by 94
Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
Mok, C. C., Penn, H. J., Chan, K. L., Tse, S. M., Langman, L. J., & Jannetto, P. J. (2016) · Arthritis Care & Research · doi:10.1002/acr.22837 · Cited by 93
Immunomodulators in SLE: Clinical evidence and immunologic actions
Durcan, L., & Petri, M. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.06.010 · Cited by 92
Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls
Bultink, I. E. M., de Vries, F., van Vollenhoven, R., & Lalmohamed, A. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa267 · Cited by 93
Cardiovascular Involvement in Autoimmune Diseases
Amaya‐Amaya, J., Montoya-Sánchez, L., & Rojas‐Villarraga, A. (2014) · BioMed Research International · doi:10.1155/2014/367359 · Cited by 97
Systemic lupus erythematosus risk factors for coronary artery calcifications
Romero‐Díaz, J., Vargas-Vorácková, F., Kimura‐Hayama, E., Cortázar-Benítez, L. F., Gijón-Mitre, R., Críales-Vera, S., Cabiedes, J., Iñiguez-Rodríguez, M. D. R., Lara-Garcia, E. A., Núñez‐Álvarez, C. A., et al. (2011) · Rheumatology · doi:10.1093/rheumatology/ker307 · Cited by 91
Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
Castrejón, I., Tani, C., Jolly, M., Huang, A., & Mosca, M. (2014) · PubMed · Cited by 89
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
Neto, E. T. D. R., Kakehasi, A. M., Pinheiro, M. A. A., Ferreira, G. A., Marques, C. D. L., da Mota, L. M. H., Paiva, E. D. S., Pileggi, G. S., Sato, E. I., Gomides, A. P. M., et al. (2020) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-020-00134-8 · Cited by 88
Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis
Urowitz, M. B., Ohsfeldt, R. L., Wielage, R. C., Kelton, K. A., Asukai, Y., & Ramachandran, S. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214043 · Cited by 88
Atherosclerosis in Systemic Lupus Erythematosus
Stojan, G., & Petri, M. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31829dd857 · Cited by 86
Towards new avenues in the management of lupus glomerulonephritis
Mok, C. C. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.174 · Cited by 84
Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus
Floris, A., Piga, M., Mangoni, A. A., Bortoluzzi, A., Erre, G. L., & Cauli, A. (2018) · Mediators of Inflammation · doi:10.1155/2018/3424136 · Cited by 84
Lupus in Latin-American patients: lessons from the GLADEL cohort
Pons‐Estel, G., Catoggio, L. J., Cardiel, M. H., Bonfá, E., Caeiro, F., Sato, E. I., Massardo, L., Molina, J. F., Toledano, M. G., Barile-Fabris, L. A., et al. (2015) · Lupus · doi:10.1177/0961203314567753 · Cited by 82
Venous Thrombosis in the Antiphospholipid Syndrome
Farmer-Boatwright, M. K., & Roubey, R. A. S. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.182204 · Cited by 82
Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions
Ugarte, A., Danza, Ã., & Ruiz‐Irastorza, G. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000527 · Cited by 79
Self-citation
Current and emerging treatment options in the management of lupus
Jordan, N., & D’Cruz, D. P. (2016) · ImmunoTargets and Therapy · doi:10.2147/itt.s40675 · Cited by 78
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome
Belizna, C. C., Pregnolato, F., Abad, S., Alijotas‐Reig, J., Amital, H., Amoura, Z., Andréoli, L., Andrès, E., Aouba, A., Bilgen, Ş. A., et al. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.05.012 · Cited by 78
The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies
Sciascia, S., Branch, D. W., Levy, R. A., Middeldorp, S., Pavord, S. R., Roccatello, D., Ruiz‐Irastorza, G., Tincani, A., Khamashta, M. A., Schreiber, K. I., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-06-0491 · Cited by 79
Self-citation
Management of antiphospholipid syndrome
Tuthill, J. I., & Khamashta, M. A. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.05.002 · Cited by 78
TLR9 Blockade Inhibits Activation of Diabetogenic CD8+ T Cells and Delays Autoimmune Diabetes
Zhang, Y., Lee, A. S., Shameli, A., Geng, X., Finegood, D. T., Santamaría, P., & Dutz, J. P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901814 · Cited by 80
Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus
Martinez-Berriotxoa, A., Ruiz-Irastorza, G., Egurbide, M.-V., Garmendia, M., Gabriel Erdozain, J., Villar, I., & Aguirre, C. (2007) · Lupus · doi:10.1177/0961203307083316 · Cited by 76
Self-citation
Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort
Mok, C. C., Tse, S. M., Chan, K. L., & Ho, L. Y. (2017) · Lupus · doi:10.1177/0961203317739129 · Cited by 76
Hydroxychloroquine: the cornerstone of lupus therapy
Ruiz‐Irastorza, G., & Khamashta, M. A. (2008) · Lupus · doi:10.1177/0961203307086643 · Cited by 76
Self-citation
Antiphospohlipid syndrome in obstetrics
Danza, Ã., Ruiz‐Irastorza, G., & Khamashta, M. A. (2011) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2011.10.006 · Cited by 74
Self-citation
Guidelines on the investigation and management of antiphospholipid syndrome
Arachchillage, D. J., Platton, S., Hickey, K. P., Chu, J., Pickering, M. C., Sommerville, P., MacCallum, P., & Breen, K. A. (2024) · British Journal of Haematology · doi:10.1111/bjh.19635 · Cited by 77

Authors: Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., Erdozain, J.-G., & Aguirre, C.
Affiliations: Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain,
University of the Basque Country (ES)
Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
ORCID: Pijoan, J-I
Erdozain, J-G
Venue: Lupus
Publisher: SAGE Publications
Published: 2006-09
Volume: 15
Issue: 9
Pages: 577-583
ISSN: 0961-2033 (ISSN-L)
1477-0962
DOI: 10.1177/0961203306071872
OpenAlex: W2014873778
Cited by: 411
References: 48
Citations by year: 2026: 11 · 2025: 7 · 2024: 30 · 2023: 24 · 2022: 19 · 2021: 22 · 2020: 29 · 2019: 23 · 2018: 27 · 2017: 17 · 2016: 18 · 2015: 20 · 2014: 28 · 2013: 22 · 2012: 25
FWCI: 11.16
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Lupus (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: antimalarial drugs, systemic lupus erythematosus, thrombosis, survival, antiphospholipid antibodies, cardiovascular complications, mortality, hydroxychloroquine, chloroquine
MeSH terms: Adult, Analysis of Variance, Antimalarials, Cause of Death, Female, Follow-Up Studies, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Prospective Studies, Research Design, Risk Factors, Spain, Thrombosis, Time Factors, Survival Rate, Proportional Hazards Models, Survival Analysis, Treatment Failure, Endpoint Determination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks